We present a case of structural and functional changes compatible with didanosine retinopathy in a patient who also developed non-cirrhotic portal hypertension.
WhitcupSM, ButlerKM, CarusoR. Retinal toxicity in human immunodeficiency virus-infected children treated with 2′,3′-dideoxyinosine.Am J Ophthalmol1992; 113: 1–7
2.
WhitcupSM, ButlerKM, PizzoPA, NussenblattRB. Retinal lesions in children treated with dideoxyinosine.N Engl J Med1992; 326: 1226–7
3.
WhitcupSM, DastgheibK, NussenblattRB, WaltonRC, PizzoPA, ChanCC. A clinicopathologic report of the retinal lesions associated with didanosine.Arch Ophthalmol1994; 112: 1594–8
4.
NguyenA, ShayL, WyvillK. Pilot study of sequential therapy with Zidovudine plus Acyclovir, Dideoxyinosine, and Dideoxycytidine in patients with severe immunodeficiency virus infection.J Infect Dis1993; 168: 810–7
5.
CoboJ, RuizMF, FigueroaMS. Retinal toxicity associated with didanosine in HIV-infected adults.AIDS1996; 10: 1297–300
6.
MuralhaA, ReisnerM, CuriA. Retinopathy associated with the use of didanosine.Arq Bras Oftalmol2001; 64: 465–7
7.
FernandoAI, AndersonOA, HolderGE, MitchellSM. Didanosine-induced retinopathy in adults can be reversible.Eye (Lond)2006; 20: 1435–7
8.
LambertJS, SeidlinM, ValentineFT, ReichmanRC, DolinR. Didanosine: long-term follow-up of patients in a phase 1 study.Clin Infect Dis1993; 16 (Suppl. 1): S40–5
9.
LambertJS, SeidlinM, ReichmanRC. 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial.N Engl J Med1990; 322: 1333–40
10.
KovariH, LedergerberB, UlrichP. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study.Clin Infect Dis2009; 49: 626–35
11.
CotteL, BénetT, BillioudC. The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: a case control study.J Hepatology2011; 54: 489–96
12.
WatersL, MaitlandD, MoyleGJ. Tenofovir and didanosine: a dangerous liaison.AIDS Read2005; 15: 403–6, 413
13.
DíazHA, CallejoAM, RodriguezJG, Non-cirrhotic portal hypertension in human immunodeficiency virus infected patients: a new challenge in antiretroviral therapy era.The Open AIDS J2011; 5: 59–61
14.
ChenCH, Vazquez-PaduaM, ChengYC. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity.Mol Pharmacol1991; 39: 625–8
15.
SchwartzSG, MielerWF. Medications and retinal toxicity.Ophthalmol Clin N Am2002; 15: 517–28
